Dilanubicel

Phase 2Cell therapy

FFred Hutchinson Cancer Center

Dilanubicel is one of 7 biologic programs targeting Acute Biphenotypic Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Biphenotypic LeukemiaActive, not recruiting

Acute Biphenotypic LeukemiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Acute Biphenotypic Leukemia

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

3 2

Tepadina

Jazz Pharmaceuticals

Phase 2

2 3

Trexall

Jazz Pharmaceuticals

Phase 2

1 4

Cytoxan

BBaxter Healthcare Corporation

Phase 2

3 5

Busulfex

Akero Therapeutics

Phase 2

1 6

Prograf

VVeloxis Pharmaceuticals

Phase 2

1 7

Dilanubicel

FFred Hutchinson Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Acute Biphenotypic Leukemia

NCT03399773

Clinical

Trials by Indication[1]

Hematologic Cancer1 trial

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

Terminated·FFred Hutchinson Cancer Center·Phase 2·NCT04083170·1 enrolled

Acute Biphenotypic Leukemia1 trial

Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03399773·31 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dilanubicel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dilanubicel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dilanubicel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fred Hutchinson Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: FFred Hutchinson Cancer Center

Dilanubicel

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Hematologic Cancer1 trial

Acute Biphenotypic Leukemia1 trial

References

Drug Info

Quick Facts

Related News